围术期β受体阻滞剂随机试验在非心脏手术中的可推广性
本研究基于一项因招募失败而终止的围术期β受体阻滞剂随机对照试验,前瞻性筛查了2241例择期非心脏手术成人患者,评估其与36项已发表RCT入选标准的匹配比例。结果显示仅6.5%的患者符合全部36项试验的平均入选标准,且PRECIS-2评分越高匹配比例越高,提示现有试验入选标准过于严格、可推广性差。
要点
- 真实世界非心脏手术患者中仅6.5%符合36项围术期β受体阻滞剂RCT的平均入选标准。
- 各RCT匹配比例从53%到0%不等,显示入选标准限制性差异大。
- PRECIS-2评分越高(越实用化)的试验匹配患者比例越高(P<0.001)。
核心结论
- 围术期β受体阻滞剂试验的入选标准过于严格,无法推广至真实世界手术人群。
研究设计与样本
- 主要结局为筛查患者与36项已发表RCT(来自一项大型Cochrane荟萃分析)入选标准匹配的比例,并使用PRECIS-2评分(9分至45分)评估每项RCT的实用/解释性水平。
主要发现
- 仅小部分患者符合36项RCT各自的入选和排除标准,匹配比例范围为53%至0%。
- 符合全部36项RCT入选标准的平均患者比例为6.5%(n=145;95%CI 6.3-6.6)。
- PRECIS-2评分越高与匹配患者比例越高相关(P<0.001)。
临床怎么用
- 解读围术期β受体阻滞剂RCT证据时需考虑其入选标准严格、外推至真实手术人群受限。
- 设计未来围术期试验时应放宽入选标准以提高可推广性。
局限性
- 本研究为单中心学术三级医疗机构的前瞻性队列,结果外推需谨慎。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The limited applicability of evidence from RCTs in real-word practice is considered a potential bottleneck for evidence-based practice but rarely systematically assessed. Using our failure to recruit patients into a perioperative beta-blocker trial, we set out to analyse the restrictiveness and generalisability of trial eligibility criteria in a real-world cohort. METHODS: We prospectively included adult patients (≥18 yr) scheduled for elective noncardiac surgery at an academic tertiary care facility who were screened for inclusion in a planned perioperative beta-blocker RCT, which was terminated owing to recruitment failure. The primary outcome was the proportion of screened patients who matched the eligibility criteria of 36 published RCTs included in a large Cochrane meta-analysis on perioperative beta-blocker therapy. The pragmatic/explanatory level of each RCT was assessed using the PRagmatic-Explanatory Continuum Indicator Summary 2 (PRECIS-2) score, which ranges from 9 points (indicating a very explanatory study) to 45 points (indicating a very pragmatic study). RESULTS: A total of 2241 patients (54% female, n=1215; 52 [standard deviation, 20] yr) were included for the assessment of trial eligibility between October 2015 and January 2016. Only a small proportion of patients matched the inclusion and exclusion criteria for each of the 36 RCTs, ranging from 53% to 0%. The average proportion of patients who did match the eligibility criteria of all 36 RCTs was 6.5% (n=145; 95% confidence interval, 6.3-6.6). A higher PRECIS-2 score was associated with a higher proportion of matching patients (P<0.001). CONCLUSIONS: Trial eligibility criteria in perioperative beta-blocker therapy trials are overly restrictive and not generalisable to a real-world surgical population. CLINICAL TRIAL REGISTRATION: EudraCT#: 2015-002366-23.
引用
- Titz M, Schwameis M, Kienbacher C, et al. Generalisability of randomised trials evaluating perioperative β-blocker therapy in noncardiac surgery. Br J Anaesth. 2020. PMID: 32888632. doi:10.1016/j.bja.2020.08.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。